Harvard Pilgrim has updated our commercial prior authorization policy for the medication Opdivo to include coverage for an additional treatment indication. Following an FDA label update, Opdivo is now covered for the treatment of patients with intermediate- or poor-risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab.